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MHC class II-restricted epitopes
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Abrogating an unwanted immune response toward a specific antigen without
compromising the entire immune system is a hoped-for goal in immunotherapy. Instead of
manipulating dendritic cells and suppressive regulatory T cells, depleting effector T cells
or blocking their co-stimulatory pathways, we describe a method to specifically inhibit
the presentation of an antigen eliciting an unwanted immune reaction. Inclusion of an
oxidoreductase motif within the flanking residues of MHC class II epitopes polarizes CD4+
T cells to cytolytic cells capable of inducing apoptosis in antigen presenting cells (APCs)
displaying cognate peptides through MHC class II molecules. This novel function results
from an increased synapse formation between both cells. Moreover, these cells eliminate
by apoptosis bystander CD4+ T cells activated at the surface of the APC. We hypothesize
that they would thereby block the recruitment of cells of alternative specificity for the same
autoantigen or cells specific for another antigen associated with the pathology, providing
a system by which response against multiple antigens linked with the same disease can
be suppressed. These findings open the way toward a novel form of antigen-specific
immunosuppression.
Keywords: MHC class II epitopes, oxidoreductase activity, cytolytic CD4+ T cells, apoptosis, immune suppression
Introduction: A Distinct Subset of CD4+ T Cells
CD4+ T cells with cytotoxic activity have been occasionally described over the past 30 years (1–3).
Their role in infection has been recognized, both during natural disease (4–6) and as an outcome
of immunization (7, 8). Moreover, their antitumor potential seems to have been underestimated
(9). Despite recent advances characterizing these cells as end-stage differentiated cells (10) and
describing their cytolytic function through Fas–Fas ligand interaction and perforin/granzymes
activity (11), the conditions under which they can be elicited remain poorly understood and their
physiological relevance has not been fully established (12, 13).
CD4+ T cells can also differentiate into regulatory T cells (Tregs). Natural Tregs are selected in
the thymus and show specificity for auto as well as alloantigens (14). The identification of Foxp3 as
a master transcription regulator and subsequent gene profiling (15) have established their identity,
with a phenotype, including constitutive expression of CD25, GITR, ICOS, CTLA-4, and CD103,
production of IL-10, and absence of CD127 (16). Natural Tregs are essential for the control of
autoimmunity and have shown a therapeutic potential in experimental autoimmune diseases and
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allograft rejection (17), but their use is still limited by difficulties
of expanding stable populations, their lack of antigen specificity
and concern of non-specific effect related to the production of
suppressive cytokines (18).
Over recent years, a second category of Tregs has been
described, called adaptive or induced Tregs (iTregs). These cells
can be obtained both in vitro in absence of antigen by incu-
bation with IL-10, vitamin D3, dexamethasone, or IFN-α (Tr1)
and in vivo by antigen administration via the oral route (Th3)
or by peptide administration in the absence of adjuvant via the
transmucosal route (19) or subcutaneously (20). The molecu-
lar mechanisms underlying the function of iTregs are poorly
understood, reflecting their heterogeneity. They do not express
Foxp3, except for transient expression in the presence of TGF-
β (21). Some iTregs overexpress T-bet when elicited by peptide
administration without adjuvant (19), or GATA-3 after intranasal
administration of ovalbumin (22), suggesting that the phenotype
of iTregs and their functional properties vary according to ini-
tial T cell lineage commitment and degree of maturation (23).
iTregs share an anergic status and limited capacities for in vitro
expansion (18).
We describe here what we consider as a bona fide new and
distinct functional subset of CD4+ T cells. The uniqueness of
these cells are based on two key observations: one, these cells can
be generated from any of the major subsets tested so far, including
highly polarized Th1, Th2, and Th17 cells; two, in parallel to
acquisition of apoptosis-inducing properties, such cells acquire a
phenotype of terminally differentiated effector memory cells.
Induction of Cytolytic CD4+ T Cells
Formation of a synapse in between an antigen presenting cell
(APC) expressing aMHC class II molecule presenting an antigen-
derived epitope and a CD4+ T cell constitutes the earliest step
of recognition by the adaptive immune system, and as such
represents an ideal target for intervention.
The crystal structure of a MHC class II molecule shows that
the cleft in which an epitope can be accommodated remains
open on both sides, providing the opportunity to bind epitopes
exceeding the sequence bound to the cleft. Thus, epitopes up to
20 amino acids have been described as being presented by class
II molecules, although the sequence recognized by the TCR is
limited to 8–9 amino acids. Retrospectively, it is surprising to
realize that this general observation has attracted very limited
attention. Residues located outside of the cleft, the so-called flank-
ing residues, have been considered almost exclusively to identify
their role in strengthening either the binding of the epitope in
the cleft or alternatively the strength of TCR binding. Indeed, the
nature of the amino acids just adjacent to positions P1 and P9,
which correspond to the first and the last anchoring residues for
the epitope, has been shown to influence such binding (24). This is
all themore surprising as the strength of the synapse in between an
APC and aCD4+ T cells is known to be one of the factors deciding
upon the fate of the CD4+ T cells (25). Recent experiments have,
however, demonstrated that modifications in flanking residues of
a variety of epitopes can affect TCR recognition and CD4+ T cell
function (26, 27).
Earlier research on one of the major class II-restricted T cell
epitopes (p21–35) of the Der p 2 allergen derived from the house
dust mite, Dermatophagoides pteronyssinus, showed that this pep-
tide elicited CD4+ T cells, which appeared to eliminate APCs
in culture (28, 29). The determinants in this peptide sequence
that lead to this remarkable property were unknown. Extensive
investigation of this epitope unveiled the presence of an intact
amino terminal oxidoreductasemotif (CxxSmotif, whereC stands
for cysteine, S for serine, and x for any other amino acid) located
within the flanking residues. This motif is characteristic of mono-
cysteinic glutaredoxins (30), which are known to exert a nucle-
ophilic attack on disulfide bridges and to create as such stable
intermediates (31).
Amino acid substitution assays demonstrated that the presence
of this motif in the Der p 2 (p21–35) sequence is essential for
acquisition of cytolytic activities toward APCs (32). Introduc-
ing such motif in the flanking residues of other T cell epitopes
demonstrates that the cytolytic properties are not limited to the
specific Der p 2 epitope sequence context. The natural CxxS
motif was further optimized by introducing a second cysteine,
making a CxxCmotif (33) presenting a higher oxidoreductase and
reinforcing the cytolytic properties. This novel function results
from an increased synapse formation between the APC and the
antigen-specific CD4+ T cells. Carlier et al. further demonstrated
that the target for the reduction was a constrained disulfide bridge
located in the second extracellular domain of the CD4 molecule
itself.
Strength of Synapse Formation and
Acquisition of a Cytolytic Phenotype
The strength of the synapse is a determining factor for the fate
of CD4+ T cells, low strength leads to ignorance or induction of
anergy, while excessive strength could prime activation-induced
cell death. The CD4 molecule binds via its first extracellu-
lar domain to residues located in the MHC class II molecule.
By doing so, the synapse itself, which is by nature of low
affinity, is physiologically strengthened. Reducing the disulfide
bridge allows the formation of homodimers or polymers of CD4,
thereby further strengthening the synapse, as demonstrated by
increased number of doublets in between APCs and CD4+
T cells (32).
CD4 contains an intracellular domain with subdomains for
the recruitment of kinases associated with early signaling. Expo-
sure of naïve CD4+ T cells to epitopes with a CxxC motif
located in flanking residues results in increased rates of recruit-
ment of Lck and subsequently ZAP70, forming an activation
complex with CD3. An increase in the kinetics and extent of
CD3ζ phosphorylation and degradation further indicated that
the increase in the activation followed a physiological path-
way. Furthermore, we observed that the increased rate of this
early signaling complex was followed by sustained activation of
PI3K and AKT. Phosphorylation of AKT is a crucial event for
cells, as it drives the proliferation capacity of the cells, their
metabolism, and phenotype adoption. Thus, increased phospho-
rylation of AKT resulted in prevention of nuclear migration
of FOXO-3a, triggered the aerobic glycolytic pathway shared
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by effector cells and activated the mTOR complex pathway
(our unpublished data). Of much interest, these activation and
metabolic properties are opposite to the ones observed with
Tregs, in which AKT activation is reduced and the metabolism
switched to oxidated lipid phosphorylation, indicating already
that on phenotypical grounds, cells exposed to epitopes contain-
ing the CxxC motif adopted a diametrically opposite phenotype
as Tregs do.
Functionally speaking, cells exposed to epitopes containing a
CxxC motif promptly adopted a phenotype of effector memory
cells, characterized by rapid loss of expression of CD62L and
high expression of CD44. Other relevant surface markers include
CD25, a characteristic shared with Tregs, and which provides
cells with the possibility of utilizing IL-2 when present at
low concentrations leading to a proliferative advantage over
alternative effector cells. Low expression of CD28 and increased
expression of CTLA-4 are also shared features with Tregs. At the
transcriptional level, cells are characterized by co-expression of
T-bet and GATA-3, considered as being exclusive from each other
in effector cells, Th1 expressing T-bet and Th2 cells expressing
GATA-3. Worth mentioning is that, under no circumstances,
it was possible to detect Foxp3, at protein or even mRNA level
(Malek Abrahimians et al., in preparation). The production of
cytokines is essentially limited to IFN-γ. FasL and granzyme B are
transcribed and the proteins produced. Both actively participate
in the induction of apoptosis of target cells, such as APCs
with which a synapse is formed. Perforin can be transcribed
but seemingly with no production of the protein. Blocking
experiments have confirmed the direct participation of both
granzyme B and FasL in the cytolytic activity of the cells, while
inhibitors of perforin showed no effect (32).
Conversion of Polarized Cells and
Induction of Bystander CD4+ T Cell
Apoptosis
We observed that polarized cells exposed to their cognate epitope
in the presence of a CxxC motif progressively lose their pheno-
typic characteristics to acquire cytolytic properties. Interestingly
enough, once the cytolytic properties are acquired, cells seem-
ingly do not revert to their initial phenotype even under highly
polarizing conditions (Carlier et al., in preparation).
The question was extended to bystander CD4+ T cells to
determine whether the technology would be effective in a multi-
epitope and multi-antigen pathology; in other words, whether
it was possible to suppress a polyclonal CD4+ T cell response
using a single epitope from a single antigen.We demonstrated that
CD4+ T cells that had acquired cytolytic potential, were capable of
eliminating by apoptosis whatever CD4+ T cells, provided these
cells were activated at the surface of the same APC. This apoptosis
occurred independently of the elimination of the APC itself (32).
Taken altogether, the combination of the possibility to con-
vert naïve or polarized cells into a cytolytic phenotype, with the
possibility to eliminate by apoptosis activated bystander CD4+
T cells, constitutes a comprehensive approach with potential for
therapeutic intervention.
Pre-Clinical Evidence Toward a
Therapeutic Application
In a model of experimental allergic asthma, as induced by nasal
instillation of recombinant allergens prepared from the house dust
mite, D. pteronyssinus, immunization with a peptide encompass-
ing a class II-restricted epitope of either Der p 1 or Der p 2 was
sufficient to eliminate the bronchial reactivity to exposure not only
to the allergen serving to induce asthma but also to an alternative
allergen. Besides, and more importantly, such a treatment elim-
inated the bronchial reactivity to a non-specific stimulus largely
used in a clinical setting, namely acetylcholine, demonstrating that
such an approach is able to reduce both specific and non-specific
bronchial reactivity.
In a model of skin graft rejection, pre-immunization of female
C57BL/6 mice with a single epitope derived from a single antigen
encoded by the Y chromosome was sufficient to obtain full toler-
ance to the grafting of a male skin. This model also established
that mice having rejected a graft, and therefore under condi-
tion of higher reactivity to alloantigens were rendered tolerant
to a subsequent graft if pretreated with the epitope of the Dby
antigen. Additionally, mice pre-immunized and having tolerated
a first graft were tolerant to a second identical graft 4months
later and with no intermediate treatment, providing an indication
of the in vivo persistence of such Dby-specific cytolytic CD4+
T cells.
In a model of multiple sclerosis, either pre-immunization with
a class II-restricted epitope from the MOG protein (a constituent
of the myelin gain) or immunization initiated weeks after dis-
ease induction, it was possible to prevent the appearance of
clinical signs or, to some extent, reduce such signs. Strikingly,
in such a model, gains of myelin were reconstituted in a con-
text in which it could be observed that the inflammatory infil-
trates in the central nervous system white matter or the spinal
cord had been completely eliminated. Interestingly, infusion of
cells, in the same model, converted in vitro to a cytolytic phe-
notype was efficient to either prevent or suppress the disease.
Noticeably, a clinical trial with patients with relapsing–remitting
multiple sclerosis has been recently initiated using the same
principle.
In a model of gene therapy, in which the immune response
toward the viral vector prohibits an effective administration
and expression of a transgene, we have demonstrated that
administration of a peptide encompassing a class II-restricted
epitope of hexon 6, a capsid protein of adenovirus 5, was
sufficient to prevent such an immune response, allowing re-
administration of the same construct, use of a significantly
lower dose of construct, use of improved transgenes, and pro-
longation of transgene expression. Considering that, in terms
of immunogenicity, adenovirus represents the worst-case sce-
nario, we surmise that alternative viruses, such as the adeno-
associated virus (AAV), would be amenable to the same
approach. Importantly, the same method could be used for gene
vaccination.
In the spontaneous non-obese diabetes (NOD) mouse model
of type 1 diabetes, immunization with a MHC class II-restricted
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epitope derived from glutamic acid decarboxylase (GAD65),
a major autoantigen, prevents autoimmune destruction of
pancreatic β-cells. Furthermore, passive transfer of in vitro
derived cytolytic CD4+ T cells also prevented diabetes. Inter-
estingly, this setting confirms that immunization with a single
epitope is sufficient to prevent autoimmunity toward multiple
antigens implicated in the disease process.
Risk Assessment
There is a theoretical risk of reversibility or conversion of cytolytic
CD4+ T cells to pathogenic effector cells. However, efforts to force
this under stringent in vitro conditions have been unsuccessful
(our unpublished data). Furthermore, the number of generated
cytolytic cells is very limited as compared to bulk of pathogenic
effector cells present in the setting of an ongoing disease, indicat-
ing that, even in case of reversibility toward an effector phenotype,
the clinical relevance of this would not be perceptible.
Although the concept makes use of a single epitope selected
from an antigen directly implicated in the disease under investiga-
tion, the very fact that cytolytic CD4+ T cells eliminate activated
bystander CD4+ T cells could, in theory, lead to elimination
of useful effector cells toward, for instance, a microorganism.
However, as the activation and cytolytic properties of the cells
requires the formation of a synapse with a cognate epitope, we
have to envision a situation in which all the immune response
toward the microorganism is elaborated at the same time and in
the same location as the response that has to be eliminated. In
a large majority of the case, and in particular in organ-specific
autoimmune diseases, the pathogenic response is elaborated in
the draining regional lymph nodes, which is not likely to be
the port of entry of the microorganism. We therefore deem that
the likelihood of increasing the susceptibility to a concomitant
infection is remote.
Any intervention modifying the fate of a cell carries the risk of
increasing tumorigenic potential. However, to evaluate this risk,
we have analyzed the caryotype of these transformed cells and
have not identified any significant alterations in comparison to
effector cells under recurrent stimulation. Moreover, measure-
ment of the telomerase activity to evaluate the status of senescence




Peptides encompassing class II-restricted epitopes have been used
in several settings in an attempt to control disease processes. Such
peptides are administered via different routes, often transmucosal,
and in absence of adjuvant. Some results have been observed in
animal models, yet very little if any in the clinic (34).
Themechanismof action of such unmodified epitopes is related
to restimulation-induced cell death (RICD) (35). This mecha-
nism is linked to the extrinsic pathway of apoptosis induction, a
mechanism associated with signaling through the TNFR super-
family, including Fas–FasL interaction and the formation of DISC,
the death-inducing signaling complex, recruiting and activat-
ing caspases 8 and 10. This is opposed to the intrinsic path-
way in which depolarization of the mitochondrial membrane
activates caspase 9. RICD prevents uncontrolled expansion of
an immune response and is responsible for the contraction
phase following an immune response, in which the number
of activated CD4+ T cells drop dramatically, to maintain a
small population entering into a cycle of memory phenotype
conversion.
The results obtained in animal experiments using unmodified
epitopes administered without adjuvant is deemed to depend on
the elimination, by the induction of apoptosis by the extrinsic
pathway, of the CD4+ T lymphocytes specific only for the very
antigen from which the epitope has been selected. This explains
the significant, though partial beneficial effect of such approach.
However, in a clinical setting, wherein a large number of antigens
are involved, the elimination of a single CD4+ T cell population
will provide very limited, if any benefit, verymuch in keepingwith
the absence of clinical efficacy (36).
In the present setting, instead of reducing the size of a sin-
gle CD4+ T cell population specific for an epitope of a single
antigen, the intrinsic pathway of apoptosis induction is used in
combination with the extrinsic pathway. Effector cells utilizing
both the intrinsic and extrinsic apoptosis induction pathways
provide an active method to eliminate effector CD4+ T cells of
alternative specificity (alternative epitopes of the same antigen and
alternative antigens) (37), i.e., eliminating amuch larger spectrum
of effector cells associated with a disease process than unmodified
epitopes. Besides, elimination of the APCs with which the synapse
is formed provides a means to prevent the recruitment of new
cells in the pathological process. These fundamental differences
in between the mode of action of cytolytic CD4+ T cells and
the mere depletion of single effector cell population establish the
superiority of the approach.
Concluding Remarks
These pre-clinical observations on oxidoreductase-containing
epitopes and their elicitation of CD4+ T cells capable of specif-
ically eliminating APCs presenting the nominal peptide opens a
door to a novel therapeutic strategy in immune disease and leads
to hypothesize that any class II-restricted T cell epitope can be
modified by addition of a oxidoreductase motif in order to induce
specific CD4+ T cells with apoptosis-inducing properties and
thus overcome any unwanted class II-restricted immune response.
The high homology in between the synapse created at MHC
class II level in mouse and in human leads to the assumption
that the observations carried out in pre-clinical models could
be extrapolated to human cells. Indeed, we have demonstrated
efficacy in converting in vitro human CD4+ T cells to a cytolytic
phenotype, allowing application to human disease in the near
future.
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